SPDR S&P Pharmaceuticals ETFSPDR S&P Pharmaceuticals ETFSPDR S&P Pharmaceuticals ETF

SPDR S&P Pharmaceuticals ETF

No trades
See on Supercharts

Key stats


Assets under management (AUM)
‪154.26 M‬USD
Fund flows (1Y)
‪−60.28 M‬USD
Dividend yield (indicated)
1.52%
Discount/Premium to NAV
−0.8%

About SPDR S&P Pharmaceuticals ETF


Issuer
State Street Corp.
Brand
SPDR
Expense ratio
0.35%
Home page
Inception date
Jun 19, 2006
Index tracked
S&P Pharmaceuticals Select Industry
Management style
Passive
XPH offers equal-weighted exposure to a narrow selection of US pharmaceutical companies, stretching across all market caps. XPH's weighting scheme causes it to be far less concentrated than the industry, which is dominated by a handful of mega-cap names like J&J, Pfizer and Merck. The fund also introduces a heavy tilt to mid- and small-caps, which makes for a rather volatile fund relative to the industry. Overall, XPH is a solid way to capture a less concentrated version of the pharma market. The index is rebalanced quarterly.

Classification


Asset Class
Equity
Category
Sector
Focus
Health care
Niche
Pharmaceuticals
Strategy
Equal
Weighting scheme
Equal
Selection criteria
Market cap
What's in the fund
Exposure type
StocksBonds, Cash & Other
Health Technology
Stock breakdown by region
100%

See all ideas 

Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.